<DOC>
	<DOCNO>NCT00003200</DOCNO>
	<brief_summary>The purpose research study develop new chemo radiotherapy regimen treatment cancer head neck patient receive induction chemotherapy ; determine high dose Taxotere safely give together radiotherapy .</brief_summary>
	<brief_title>Chemotherapy Plus Radiation Therapy Treating Patients With Squamous Cell Cancer Head Neck</brief_title>
	<detailed_description>In investigational research study investigator attempt develop new chemo radiotherapy regimen radiotherapy Taxotere combine receive induction chemotherapy . Taxotere never give together radiotherapy , high dose Taxotere safely use set unknown . Taxotere add radiotherapy gradually subsequent group 3-5 patient get large dose . Taxotere dos increase certain toxicity occur . This help investigator determine best way combine Taxotere radiotherapy use knowledge treat patient tumor like .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathology : Histologic documentation squamous cell carcinoma head neck variant ( lymphoepithelioma , undifferentiated epidermoid carcinoma , etc ) Stage : Patients enter protocol initial induction therapy , prior induction regimen , previously untreated Stage III IV ( MO ) SCCHN . This exclude patient exophytic T3N0 tumor T1N1 lesion onset induction therapy . Evaluable disease induction therapy require . Required Prior therapy : Patients enter protocol must receive therapy one follow induction regimen , except modify toxicity : PF : Cisplatin ≥ 80 mg/M2 ? course FUra ≥ 1000 mg/M2/day ≥ 4 day every ≤ 4 week CF : Carboplatinum ≥ 300 mg/M2/course FUra ≥1000mg/M2/day ≥4 day ≤ 4 week PFL5 : Cisplatin ≥ 25 mg/M2/day 5 day , FUra ≥ 800mg/M2/day day 25 ( 4 day ) Leucovorin ≥ 500 mg/M2/day 5 day , every 4 week . TPF : Taxotere , Cisplatin ≥ 100 mg/M2/day 5 day , FUra ≥ 700 mg/M2 ? day day 25 ( 4 day ) Patients treat eligible provide receive three cycle , respond 2 cycle ; 1 cycle progressive disease p. 35 archive doc Other Malignancies : Patients previous head neck cancer ineligible , except patient treat surgery sole modality 2 year prior study entry . Patients concurrent malignancy site , except limited basal cell carcinoma squamous cell carcinoma skin carcinoma situ cervix ineligible . Patient nonSCCHN malignancy within 5 year study entry , except curatively treat basal cell carcinoma squamous cell carcinoma skin carcinoma situ cervix ineligible . Other Prior Therapy : Patients previously treat radiotherapy SCCHN eligible . Patients treat form prior chemotherapy , induction therapy describe section 3.21 within last 5 year eligible . Hormonally treated patient eligible . Performance : Patients must meet following performance criterion : Performance status : 2 ECOG . Complete recovery previous diagnostic therapeutic procedure require . Nutritional status : Adequate nutritionally balance enteral intake ( 1,800 kcal/day ) . Patients require intravenous alimentation primary source calorie exclude study . Patients experience weight loss 20 % body weight three month precede presentation ineligible . Patients persistent diarrhea ineligible . Life Expectancy : Longer 3 Months Women child bear potential must pregnant history lactating time entry protocol men woman child bear potential must request use accept effective method birth control therapy . Organ Function : Biochemical hematological parameter ( obtain within 2 week study entry ) follow : Hepatic : SGOT &lt; 1.5 x ULN Alkaline Phosphatase &lt; 2.5x ULN entry . Total Bilirubin SGOT must ≤ 2 x ULN isolate value . Alkaline phosphatase must ≤ 2.5 x ULN isolate value . Hematologic : WBC 4,000/mm3 normal absolute neutrophil count ( ANC ) ; Platelet count 100,000/mm3 , Hemoglobin 10 gm/dl ( transfusion bring hemoglobin level permit clinically indicate , however , transfusion use solely order eligibility criterion ) Neurologic : Peripheral neuropathy etiology must exceed grade 1 . Cardiovascular/Pulmonary : No acute cardiac dysrhythmias unstable cardiac condition angina Other : Lack serious illness medical condition Allergies : Patients prior allergy polysorbate 80 ( see appendix ) ineligible Informed Consent : Patients must give write informed consent Followup : All patient must available monthly evaluation restaging head neck cancer clinic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III lymphoepithelioma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV lymphoepithelioma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage III lymphoepithelioma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV lymphoepithelioma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
</DOC>